HEALTHIER CHINA THROUGH INNOVATION

Established in 1999, the R&D-Based Pharmaceutical Association Committee (RDPAC), representing 46 leading multinational pharmaceutical companies with R&D capabilities, is a committee under the China Association of Enterprises with Foreign Investment (CAEFI), which in turn reports to the Ministry of Commerce of the People's Republic of China.

NEWS

RDPAC Code of Practice

November 17, 2022
A major requisite for innovation is integrity, which is also the foundation of reputation. Without ethical decision-making, there is no true innovation.

RDPAC Announces Membership Succession of Executive Committee 2022-2023

May 25, 2022
The R&D-based Pharmaceutical Association Committee (RDPAC) has announced a change in membership of the RDPAC Executive Committee 2022-2023.

Paying for Innovation to Secure Payback - To Build a Value-oriented Innovative Payment System

April 22, 2022
The 2022 Jinling Pharmoeconomics Forum and the Annual Conference of Pharmoeconomics Committee, Jiangsu Pharmaceutical Association were held online on April 16-17.

PUBLICATIONS

THE FACES OF
INNOVATION

MEETING THE CHALLENGE OF CANCER

Cancer, refers to all malignant tumors, with biological characteristics such as abnormal cell differentiation and proliferation, loss of growth control, invasiveness and metastasis. It is one of the leading causes of death worldwide, led more than 22,000 deaths every day globally. In China, about 10,000 patients are diagnosed with cancer every day, that is, about 7 patients with cancer are diagnosed every minute ...

POLICY PILLARS OF PHARMACEUTICAL INNOVATION

FOR A HEALTHIER CHINA

Discuss how to both improve patient access to innovative drugs and promote sustainabledevelopment of the medical insurance system to achieve a win-win situation.

DEEPENING THE DRUG INNOVATION ECOSYSTEM REFORM – A PLAN TO DESIGN AND BUILD CHINA’S CLINICAL RESEARCH SYSTEM

Health is the common aspiration of all mankind, and a healthy China constitutes an integral part of the “China Dream”.